Suboxone Lawsuits in 2026: the Tooth Decay Claims, FDA Warning and Who Qualifies
In 2026, thousands of Suboxone lawsuits allege that buprenorphine sublingual film caused severe tooth decay, cavities, and tooth loss. The claims rest on a January 12, 2022 FDA warning about dental injuries from mouth-dissolving buprenorphine, and they are moving forward in federal multidistrict litigation in Ohio.
Watch the explainer on our channel: Problem Solved on YouTube.
The FDA warning that changed everything
On January 12, 2022, the U.S. Food and Drug Administration issued a Drug Safety Communication warning that buprenorphine medicines dissolved in the mouth had been linked to serious dental problems: tooth decay, cavities, oral infections, and loss of teeth. The agency required a new warning about dental problems to be added to the prescribing information and the patient medication guide for all buprenorphine medicines that dissolve in the mouth. Six medicines fell under the requirement: Belbuca, Bunavail, Cassipa, Suboxone, Subutex, and Zubsolv. The FDA also issued practical guidance for patients: schedule regular dental checkups, tell providers about all medications, swish water around after the medicine has dissolved, and wait at least one hour before brushing.
What the FDA's adverse-event review actually showed
The warning was built on the FDA's review of its Adverse Event Reporting System, FAERS — the database where patients, doctors, and manufacturers report drug-related problems. The agency identified 305 dental adverse-event cases tied to transmucosal buprenorphine: 131 were classified as serious, and 71 required tooth extraction or tooth removal. Notably, 26 patients had no prior dental history, the average age was about 42, and some patients were as young as 18. Dental problems began as early as two weeks after starting treatment, with a median time to diagnosis of about two years.
What the lawsuits allege
Plaintiffs allege that Suboxone sublingual film exposes users' teeth to prolonged acidic conditions. The film is formulated at an acidic pH to help buprenorphine absorb under the tongue, and patients hold it in their mouths until it fully dissolves — daily, for months or years. The lawsuits contend the manufacturer knew or should have known about the dental-injury pattern from its own adverse-event reports but failed to warn: the original label said nothing about tooth decay, gave no instruction to rinse after use, and recommended no regular dental monitoring. That alleged omission is a classic failure to warn — a marketing defect, meaning a product sold without adequate warnings about a foreseeable risk. Defendants include Indivior Inc., the NDA holder, and Aquestive Therapeutics, the film's exclusive global manufacturer; other Indivior and Reckitt affiliates were dismissed in September 2024 after the court found they did not manufacture, distribute, or sell the film.
Where the litigation stands in 2026
The federal cases are centralized as In re Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation, MDL No. 3092, in the Northern District of Ohio before Judge J. Philip Calabrese. The Judicial Panel on Multidistrict Litigation created the MDL in early 2024 as the number of filed cases grew rapidly; panel statistics counted 1,832 actions pending as of July 1, 2026, up from roughly 51 in March 2024. There is no global Suboxone settlement yet — in mass torts, settlement talks typically follow discovery and bellwether proceedings. Compensation varies widely by case, and most settlements are confidential. If you believe you have a claim, our guide to the personal injury statute of limitations for 2026 explains the state-by-state deadlines and why the discovery rule matters when the harm surfaced years after use.
What independent research found
In December 2022, the Journal of the American Medical Association (JAMA) published a peer-reviewed study of tens of thousands of patients. It found an increased risk of adverse dental outcomes among users of sublingual buprenorphine/naloxone: the incidence of dental caries was 8.2 per 1,000 person-years for sublingual users, compared with 3.5 for transdermal buprenorphine users and 3.8 for oral naltrexone users. A separate study published in August 2023 in Current Drug Safety concluded that the findings were consistent with prior data and recommended emphasizing regular oral care for patients on orally dissolving buprenorphine. Studies do not decide lawsuits, but they shape how cases are litigated.
Who qualifies to file a claim
Lawyers reviewing these cases generally look for the same pattern. You may qualify if you were prescribed Suboxone film and afterward developed serious dental injuries such as cavities requiring root canals, crowns, extractions, dental surgery, or implants. The claim must also fit within your state's statute of limitations, and attorneys examine whether you were warned about the dental risk before the January 2022 label change. If you are considering a claim, our guide to pharmaceutical lawyers in 2026 covers drug injury claims, mass tort procedure, and how to choose the right attorney, and our guide to the best personal injury lawyers in 2026 explains contingency fees and what to ask before signing anything.
Key facts
- The FDA issued its Drug Safety Communication on January 12, 2022, warning of tooth decay, cavities, oral infections, and tooth loss with mouth-dissolving buprenorphine.
- The FDA's FAERS review found 305 dental cases, 131 of them serious, and 71 cases that required tooth extraction.
- Of those patients, 26 had no prior dental history; the average age was about 42, and problems began as early as two weeks after starting treatment.
- The cases are consolidated in MDL No. 3092 in the Northern District of Ohio, where 1,832 actions were pending as of July 1, 2026.
- A December 2022 JAMA study found 8.2 dental caries per 1,000 person-years among sublingual buprenorphine/naloxone users, compared with 3.5 for transdermal users.
Who Benefits From This — and Who Does Not
These are individual failure-to-warn cases inside a federal MDL, not a class action with an automatic payout — and there is no global settlement yet. Whether a review is worth pursuing turns on three things: the film, the injury, and the clock.
Who benefits
- Patients prescribed Suboxone film who developed serious dental injuries: The pattern lawyers look for is cavities requiring root canals, crowns, extractions, dental surgery or implants after being prescribed the film — the FDA's review found 305 dental cases, 131 serious, 71 requiring extraction.
- Patients not warned before the January 2022 label change: The original label said nothing about tooth decay, gave no instruction to rinse after use, and recommended no regular dental monitoring — attorneys examine whether you were warned about the dental risk before that change.
- Patients whose injury fits the documented pattern: Problems began as early as two weeks after starting treatment, with a median time to diagnosis of about two years, and 26 patients in the FDA review had no prior dental history — a documented timeline strengthens a review.
Who does not benefit
- People without a serious dental injury: Earlier use of the film alone, without cavities, extractions or other serious dental injuries, does not match the claimant profile these cases are built on.
- Claims outside the statute of limitations: Each state sets its own deadline, typically one to six years from when you discovered the injury and its connection to Suboxone — missing it can bar the claim entirely, which is why the discovery rule matters when harm surfaced years after use.
- Anyone expecting a set payout: There is no global Suboxone settlement in 2026 and no set payout — compensation varies widely by case depending on injury severity, treatment costs and evidence, and most mass-tort settlements are confidential.
For the deadlines that decide whether a claim can still be filed, see Personal Injury Statute of Limitations 2026: State-by-State Deadlines (Miss It and Your Case Is Worth $0).
Frequently asked questions
Who qualifies for the Suboxone tooth decay lawsuit?
You may qualify if you were prescribed Suboxone, developed serious dental injuries such as extractions, root canals, or implants, and were not warned about the dental risk. Your claim must also fall within your state's statute of limitations.
Has there been a Suboxone tooth decay settlement in 2026?
No global settlement has been announced. Cases are proceeding in Ohio's MDL, compensation varies widely by case, and most mass-tort settlements are confidential.
How much compensation can a Suboxone case bring?
There is no set payout. Compensation varies widely by case depending on injury severity, treatment costs, and evidence, and most settlements are confidential.
What is the deadline to file a Suboxone claim?
Each state sets its own statute of limitations, typically one to six years from when you discovered the injury and its connection to Suboxone. Missing the deadline can bar your claim entirely.
Who benefits from reviewing a Suboxone claim — and who does not?
A review is worth pursuing if you were prescribed Suboxone film and afterward developed serious dental injuries such as extractions, root canals or implants, were not warned about the dental risk before the January 2022 label change, and are still within your state's statute of limitations. It does not fit people without a serious dental injury, claims already outside the deadline, or anyone expecting a fixed payout — there is no global settlement and no set amount in 2026.
How do I start checking a Suboxone claim?
Start with your records: the prescription history for Suboxone film, dental records showing the injuries and their dates, and any warning information you received before January 2022. Then check your state's statute of limitations and the discovery rule, since the deadline typically runs from when you discovered the injury and its connection to Suboxone — and speak to a pharmaceutical injury attorney before the deadline passes, since missing it can bar the claim entirely.
Disclaimer: This article is general information only and is not legal advice. Consult a qualified attorney about your situation.